Download PDF
Semin Neurol 2016; 36(04): 324-329
DOI: 10.1055/s-0036-1585427
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Caring for Patients with Newly Diagnosed High-Grade Gliomas

Stuart A. Grossman
1   Department of Oncology, Medicine & Neurosurgery, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
,
Anna F. Piotrowski
2   Department of Neuro-Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
› Author Affiliations
Further Information

Publication History

Publication Date:
19 September 2016 (online)

    Permissions and Reprints

Abstract

Novel diagnostic and therapeutic information has had a major impact on the care of patients with high-grade gliomas. These advances and discoveries are highlighted using case-based discussions to focus attention on the important diagnostic and treatment decisions that commonly arise during the care of patients with newly diagnosed glioblastoma, anaplastic astrocytoma, and anaplastic oligodendroglioma.

Keywords

glioblastoma - anaplastic astrocytoma - anaplastic oligodendroglioma
 

  • References

  • 1 Kerkhof M, Vecht CJ. Seizure characteristics and prognostic factors of gliomas. Epilepsia 2013; 54 (9) (Suppl. 09) 12-17
    CrossrefPubMedGoogle Scholar
  • 2 Vecht CJ, Kerkhof M, Duran-Pena A. Seizure prognosis in brain tumors: new insights and evidence-based management. Oncologist 2014; 19 (7) 751-759
    CrossrefPubMedGoogle Scholar
  • 3 Glantz MJ, Cole BF, Forsyth PA , et al; Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neurology 2000; 54 (10) 1886-1893
    CrossrefPubMedGoogle Scholar
  • 4 Fetell MR, Grossman SA, Fisher JD , et al; New Approaches to Brain Tumor Therapy Central Nervous System Consortium. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. J Clin Oncol 1997; 15 (9) 3121-3128
    CrossrefPubMedGoogle Scholar
  • 5 Gilbert MR, Supko JG, Batchelor T , et al. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 2003; 9 (8) 2940-2949
    PubMedGoogle Scholar
  • 6 Piotrowski AF, Blakeley J. Clinical management of seizures in patients with low-grade glioma. Semin Radiat Oncol 2015; 25 (3) 219-224
    CrossrefPubMedGoogle Scholar
  • 7 Kotsarini C, Griffiths PD, Wilkinson ID, Hoggard N. A systematic review of the literature on the effects of dexamethasone on the brain from in vivo human-based studies: implications for physiological brain imaging of patients with intracranial tumors. Neurosurgery 2010; 67 (6) 1799-1815 , discussion 1815
    CrossrefPubMedGoogle Scholar
  • 8 Hegi ME, Diserens AC, Gorlia T , et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352 (10) 997-1003
    CrossrefPubMedGoogle Scholar
  • 9 Stupp R, Mason WP, van den Bent MJ , et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352 (10) 987-996
    CrossrefPubMedGoogle Scholar
  • 10 Stupp R, Hegi ME, Mason WP , et al; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10 (5) 459-466
    CrossrefPubMedGoogle Scholar
  • 11 Zarnett OJ, Sahgal A, Gosio J , et al. Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis. JAMA Neurol 2015; 72 (5) 589-596
    CrossrefPubMedGoogle Scholar
  • 12 Grossman SA, Ye X, Lesser G , et al; NABTT CNS Consortium. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 2011; 17 (16) 5473-5480
    CrossrefPubMedGoogle Scholar
  • 13 Yovino S, Kleinberg L, Grossman SA, Narayanan M, Ford E. The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Invest 2013; 31 (2) 140-144
    CrossrefPubMedGoogle Scholar
  • 14 Grossman SA, Ellsworth S, Campian J , et al. Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors. J Natl Compr Canc Netw 2015; 13 (10) 1225-1231
    PubMedGoogle Scholar
  • 15 Gerber DE, Grossman SA, Zeltzman M, Parisi MA, Kleinberg L. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro-oncol 2007; 9 (1) 47-52
    PubMedGoogle Scholar
  • 16 Hammond LA, Eckardt JR, Baker SD , et al. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol 1999; 17 (8) 2604-2613
    CrossrefPubMedGoogle Scholar
  • 17 Derr RL, Ye X, Islas MU, Desideri S, Saudek CD, Grossman SA. Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol 2009; 27 (7) 1082-1086
    CrossrefPubMedGoogle Scholar
  • 18 Yust-Katz S, Mandel JJ, Wu J , et al. Venous thromboembolism (VTE) and glioblastoma. J Neurooncol 2015; 124 (1) 87-94
    CrossrefPubMedGoogle Scholar
  • 19 Streiff MB, Ye X, Kickler TS , et al. A prospective multicenter study of venous thromboembolism in patients with newly-diagnosed high-grade glioma: hazard rate and risk factors. J Neurooncol 2015; 124 (2) 299-305
    CrossrefPubMedGoogle Scholar
  • 20 Mahindra AK, Grossman SA. Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors. J Neurooncol 2003; 63 (3) 263-270
    CrossrefPubMedGoogle Scholar
  • 21 Wen PY, Macdonald DR, Reardon DA , et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28 (11) 1963-1972
    CrossrefPubMedGoogle Scholar
  • 22 Brandes AA, Franceschi E, Tosoni A , et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008; 26 (13) 2192-2197
    CrossrefPubMedGoogle Scholar
  • 23 Kreisl TN, Kim L, Moore K , et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27 (5) 740-745
    CrossrefPubMedGoogle Scholar
  • 24 Friedman HS, Prados MD, Wen PY , et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27 (28) 4733-4740
    CrossrefPubMedGoogle Scholar
  • 25 Chinot OL, Wick W, Mason W , et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014; 370 (8) 709-722
    CrossrefPubMedGoogle Scholar
  • 26 Gilbert MR, Dignam JJ, Armstrong TS , et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014; 370 (8) 699-708
    CrossrefPubMedGoogle Scholar
  • 27 Rudà R, Bello L, Duffau H, Soffietti R. Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. Neuro-oncol 2012; 14 (Suppl. 04) iv55-iv64
    PubMedGoogle Scholar
  • 28 Ostrom QT, Gittleman H, Liao P , et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro-oncol 2014; 16 (Suppl. 04) iv1-iv63
    PubMedGoogle Scholar
  • 29 Fisher BJ, Hu C, Macdonald DR , et al. Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424. Int J Radiat Oncol Biol Phys 2015; 91 (3) 497-504
    CrossrefPubMedGoogle Scholar
  • 30 Yamahara T, Numa Y, Oishi T , et al. Morphological and flow cytometric analysis of cell infiltration in glioblastoma: a comparison of autopsy brain and neuroimaging. Brain Tumor Pathol 2010; 27 (2) 81-87
    CrossrefPubMedGoogle Scholar
  • 31 Mehta MP, Won M, Shaw EG , et al. Mature survival data from RTOG 9802: A phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) for adult patients with high-risk low-grade glioma (LGG). J Clin Oncol 2014; 90 (1) S37-S38
    PubMedGoogle Scholar
  • 32 Eckel-Passow JE, Lachance DH, Molinaro AM , et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 2015; 372 (26) 2499-2508
    CrossrefPubMedGoogle Scholar
  • 33 Pignatti F, van den Bent M, Curran D , et al; European Organization for Research and Treatment of Cancer Brain Tumor Cooperative Group; European Organization for Research and Treatment of Cancer Radiotherapy Cooperative Group. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002; 20 (8) 2076-2084
    CrossrefPubMedGoogle Scholar
  • 34 Cairncross G, Wang M, Shaw E , et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013; 31 (3) 337-343
    CrossrefPubMedGoogle Scholar
  • 35 Boyle FM, Eller SL, Grossman SA. Penetration of intra-arterially administered vincristine in experimental brain tumor. Neuro-oncol 2004; 6 (4) 300-305
    PubMedGoogle Scholar